Search Results - "Mace, Kenneth"

Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing by Fineman, Mark, Flanagan, Shawn, Taylor, Kristin, Aisporna, Maria, Shen, Larry Z., Mace, Kenneth F., Walsh, Brandon, Diamant, Michaela, Cirincione, Brenda, Kothare, Prajakti, Li, Wen-I, MacConell, Leigh

“…Background and Objectives Exenatide is a glucagon-like peptide-1 receptor agonist, available in an immediate-release (IR), twice-daily formulation, which…”
Get full text

Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1 by Parkes, David G, Mace, Kenneth F, Trautmann, Michael E

“…The GLP-1 receptor agonist exenatide is synthetic exendin-4, a peptide originally isolated from the salivary secretions of the Gila monster. Exenatide was…”
Get more information

Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects by de la Peña, Amparo, Riddle, Matthew, Morrow, Linda A, Jiang, Honghua H, Linnebjerg, Helle, Scott, Adam, Win, Khin M, Hompesch, Marcus, Mace, Kenneth F, Jacobson, Jennie G, Jackson, Jeffrey A

“…OBJECTIVE: Human regular U-500 (U-500R) insulin (500 units/mL) is increasingly being used clinically, yet its pharmacokinetics (PK) and pharmacodynamics (PD)…”
Get full text

Effect of renal impairment on the pharmacokinetics of exenatide by Linnebjerg, Helle, Kothare, Prajakti A., Park, Soomin, Mace, Kenneth, Reddy, Shobha, Mitchell, Malcolm, Lins, Robert

“…What is already known about this subject • Nonclinical studies have shown that exenatide is primarily cleared by the renal system. • It was not known to what…”
Get full text

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes by Linnebjerg, Helle, Park, Soomin, Kothare, Prajakti A., Trautmann, Michael E., Mace, Kenneth, Fineman, Mark, Wilding, Ian, Nauck, Michael, Horowitz, Michael

“…To evaluate the effect of exenatide on gastric emptying (GE) in type 2 diabetes using scintigraphy. Seventeen subjects with type 2 diabetes participated in a…”
Get full text

Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects by Sinha, Vikram P., Choi, Siak Leng, Soon, Danny Kwang Wei, Mace, Kenneth F., Yeo, Kwee Poo, Lim, Shufen T. H., Howey, Daniel C.

“…LY2605541 is a novel basal insulin analog with a prolonged duration of action. Two Phase I studies assessed LY2605541 pharmacokinetics (PK), glucodynamics…”
Get full text

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients with Type 2 Diabetes by IWAMOTO, Kazuya, NASU, Risa, YAMAMURA, Ayuko, KOTHARE, Prajakti A., MACE, Kenneth, WOLKA, Anne M., LINNEBJERG, Helle

“…This randomized, placebo-controlled, double-blind, parallel study assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once…”
Get full text

Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Asian Men by Soon, Danny, Kothare, Prajakti A., Linnebjerg, Helle, Park, Soomin, Yuen, Eunice, Mace, Kenneth F., Wise, Stephen D.

“…Exenatide, a treatment for type 2 diabetes, slows gastric emptying as part of its pharmacologic action and may alter the absorption of concomitant oral drugs…”
Get full text

Pharmacokinetics of the Long-Acting Basal Insulin LY2605541 in Subjects With Varying Degrees of Renal Function by Linnebjerg, Helle, Choi, Siak Leng, Lam, Eric Chen Quin, Mace, Kenneth F., Hodgson, Teri S., Sinha, Vikram P.

“…The pharmacokinetics of LY2605541 (basal insulin peglispro), a novel long‐acting basal insulin analogue, was evaluated in 5 groups of subjects with varying…”
Get full text

Effect of Exenatide on the Steady-State Pharmacokinetics of Digoxin by Kothare, Prajakti A., Soon, Danny K. W., Linnebjerg, Helle, Park, Soomin, Chan, Clark, Yeo, Adeline, Lim, Maggie, Mace, Kenneth F., Wise, Stephen D.

“…This open‐label study investigated the effect of exenatide coadministration on the steady‐state plasma pharmacokinetics of digoxin. A total of 21 healthy male…”
Get full text

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients with Type 2 Diabetes by KAZUYA IWAMOTO, RISA NASU, AYUKO YAMAMURA, PRAJAKTI A.KOTHARE, KENNETH MACE, ANNE M.WOLKA, HELLE LINNEBJERG

“…This randomized, placebo-controlled, double-blind, parallel study assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once…”
Get full text

Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects by Keller, Jutta, Trautmann, Michael E., Haber, Harry, Tham, Lai San, Hunt, Tamsin, Mace, Kenneth, Linnebjerg, Helle

“…Exenatide is a glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes and has been shown to lower blood glucose through multiple…”
Get full text

Correlation between in vivo induction of cytokine gene expression by flavone acetic acid and strict dose dependency and therapeutic efficacy against murine renal cancer by Mace, K F, Hornung, R L, Wiltrout, R H, Young, H A

“…The investigational chemotherapeutic drug flavone acetic acid (FAA) acts as an immunomodulator by augmenting natural killer activity in both humans and rodents…”
Get full text

Adriamycin-induced modulation of host defenses in tumor-bearing mice by MACCUBBIN, D. L, WING, K. R, MACE, K. F, HO, R. L. X, EHRKE, M. J, MIHICH, E

“…Using the C57BL/6/EL4 tumor model, studies were carried out to demonstrate the feasibility of administering Adriamycin (ADM) in therapeutic doses and schedules…”
Get full text

Role of tumor necrosis factor in macrophage activation and tumoricidal activity by MACE, K. F, EHRKE, M. J, HORI, K, MACCUBBIN, D. L, MIHICH, E

“…Tumor necrosis factor (TNF)-sensitive (LM) and -insensitive (P815) target cell lines were used to examine the role of TNF in both the activation and lytic…”
Get full text

Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus (对中国2型糖尿病患者单次和多次给予艾塞那肽周制剂的药代动力学、安全性和耐受性研究) by Cui, Yi Min, Guo, Xiao Hui, Zhang, Dong Mei, Tham, Lai San, Tang, Cheng Cai, Mace, Kenneth, Linnebjerg, Helle

“…Background This open‐label, single‐period study assessed the pharmacokinetics, safety, tolerability, and pharmacodynamics of exenatide once weekly (q.w.),…”
Get full text

Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects. Diabetes Care 2011;34:2496–2501 by de la Peña, Amparo, Riddle, Matthew, Morrow, Linda A., Jiang, Honghua H., Linnebjerg, Helle, Scott, Adam, Win, Khin M., Hompesch, Marcus, Mace, Kenneth F., Jacobson, Jennie G., Jackson, Jeffrey A.

Get full text

Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Mellitus by Kothare, Prajakti A., Linnebjerg, Helle, Isaka, Yoshitaka, Uenaka, Kazunori, Yamamura, Ayuko, Yeo, Kwee Poo, de la Peña, Amparo, Teng, Choo Hua, Mace, Kenneth, Fineman, Mark, Shigeta, Hirofumi, Sakata, Yukikuni, Irie, Shin

“…In this single‐blind, parallel, placebo‐controlled study, the pharmacokinetics, pharmacodynamics, tolerability, and safety of subcutaneous exenatide were…”
Get full text

Modification of host antitumor defense mechanisms in mice by progressively growing tumor by MACCUBBIN, D. L, MACE, K. F, EHRKE, M. J, MIHICH, E

“…The EL4 lymphoma in C57BL/6 mice was used as a model to examine the effect of progressive tumor growth on a variety of cell mediated cytolytic effector…”
Get full text

Phantoms, ghosts, and such things: A reply to Adams and Peery by Mace, Kenneth C

“…Defends the inclusion of the journal Child Development Monographs in K. C. Mace and H. D. Warner's (1973) and D. Koulack and H. J. Keselman's studies ranking…”
Get full text